RBC Capital upgraded Fisher & Paykel Healthcare to Sector Perform from Underperform with a price target of NZ$21, up from NZ$20. The analyst cites valuation for the upgrade after the company maintained its fiscal 2024 outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.